Background {#S0001}
==========

Liver cancer (LC) is the sixth most common cancer and the second largest cause of cancer mortality worldwide, with nearly 800,000 cases in 2012.[@CIT0001] The highest incidence rates of LC were observed in Eastern Asia, South-Eastern Asia, Northern Africa and Southern Africa, with China accounting for about 50% of all cases.[@CIT0002] LC is usually caused by underlying diseases, including hepatitis B virus (HBV), mycotoxins, poor diet and inactivity.[@CIT0001] However, there is a startling lack of treatments on LC.

MiRNA is regarded as the critical elements in cancer development and involved in major cellular processes of cancer, such as cell differentiation, proliferation, migration, and apoptosis.[@CIT0003]--[@CIT0005] Further studies have shown that miRNAs can be used as tumor initiation factors, invasion and metastasis factors, tumor suppressor factors, etc. Hence, MiRNA may have a potential role in the development of new cancer control methods.[@CIT0004],[@CIT0006]

*MIR137HG* (*MIR137* Host Gene) is an RNA Gene and is affiliated with the miRNA class. Currently, researches have shown that the promoter of *MIR137HG* is highly methylated in colorectal cancer,[@CIT0007] malignant pleural mesothelioma,[@CIT0008] and oral squamous cell carcinoma.[@CIT0009] *MIR137* is known to be a tumor suppressor, and the increased methylation level of *MIR137HG* in malignant pleural mesothelioma cell lines and colorectal cancer affects the occurrence and development of corresponding cancers.[@CIT0007] However, there are no previous studies have investigated the association of LC risk and *MIR137HG* polymorphisms.

Hence, a case-control study was performed in 432 LC patients and 430 healthy controls to evaluate the possible association of LC and *MIR137HG* polymorphisms among Chinese Li population. The investigation was expected to further deepen our understanding regarding the pathogenesis of LC and serve as non-invasive biomarkers for LC.

Materials and Methods {#S0002}
=====================

Ethics Statement {#S0002-S2001}
----------------

Our research was approved by the Ethics Committee of the Second Affiliated Hospital of Hainan Medical College (Ethics number: HZ2015-11), and all procedures were conducted in accordance with the ethical standards of the Declaration of Helsinki and following national and international guidelines. Written informed consent was obtained from each participant after the study was fully explained.

*Study subjects*862 individuals, consisting of 430 healthy people and 432 patients with LC, were recruited from the Second Affiliated Hospital of Hainan Medical College, Hainan Province, China. All LC patients were newly diagnosed and had not received relevant antitumor therapy, such as surgical treatment, radiotherapy, chemotherapy and biotherapy. They were diagnosed with liver cancer by routine examination, imaging (such as B-ultrasonic wave, CT and nuclear magnetic resonance) and histopathological examination. Our case group also excluded patients with the following diseases: liver diseases like hepatitis and liver cirrhosis induced by diabetes, fatty liver, metabolic disorder and vascular disease, primary and secondary biliary cirrhosis, recurrent liver cancer, metastatic liver cancer, hepatitis A, C, D, and E, autoimmune hepatitis, etc. Control subjects, without any history of tumor or chronic diseases, were healthy individuals selected from the physical examination center of the Second Affiliated Hospital of Hainan Medical College, Hainan Province, China. All the participants were Li nationality from Hainan Province of China and they have no relationship with each other.

SNP Selection and Genotyping {#S0002-S2002}
----------------------------

According to the 1000 Genomes Project ([<http://www.1000genomes.org/>]{.ul}) and dbSNP ([<https://www.ncbi.nlm.nih.gov/projects/SNP/>]{.ul}) database, five label single nucleotide polymorphisms (SNPs) (rs12138817, rs9440302, rs1198574, rs17371457 and rs7554283) with minor allele frequency (MAF) \> 5% were finally selected to evaluate the effect of *MIR137HG* polymorphisms on LC susceptibility.

Peripheral blood samples from all participants were collected in tubes coated with EDTA and were stored at 80°C. Following the manufacturer's guidelines, genomic DNA was extracted from participants' peripheral blood samples using the GoldMag whole blood genomic DNA purification kit (GoldMag Co. Ltd., Xi an, China). DNA concentration was measured with NanoDrop 2000 spectrophotometer (Thermo Scientific, Waltham, MA, USA).[@CIT0010] The primers for the amplification reactions were designed using the Agena Bioscience Assay Design Suite V2.0 software to perform (Agena Bioscience, San Diego, CA, USA, [<https://agenacx.com/online-tools/>]{.ul}).[@CIT0011] Primers used for this study were listed in [[Supplementary Table S1](https://www.dovepress.com/get_supplementary_file.php?f=225669.docx)]{.ul}. The MassARRAY iPLEX platform and Agena Bioscience TYPER version 4.0 software were used for SNP genotyping and data analysis, respectively.

SNP Functional Evaluation {#S0002-S2003}
-------------------------

HaploReg v4.1 ([<https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php>]{.ul}) was used to predict the potential functions of SNPs in *MIR137HG* gene.

Statistical Analysis {#S0002-S2004}
--------------------

SPSS software package (version 20.0; SPSS Inc., Chicago, IL, USA) was adopted to process data, and *P* \< 0.05 was regarded as statistically significant.[@CIT0012],[@CIT0013] Hardy--Weinberg equilibrium (HWE) *P* values obtained from exact tests[@CIT0014] were used to evaluate whether the control group meets HWE. The distributions of genotype and allele frequencies between cases and controls were compared by χ^2^ tests. The genotype-specific risks were estimated as odds ratios (ORs) and 95% confidence interval (CI) based on logistic regression model analysis.[@CIT0015] Stratified analyses were also performed to assess the relationship between each SNP and the risk of LC in different subgroups. Finally, linkage disequilibrium (LD) analyses and haplotype analyses were performed using the SHEsis software ([<http://analysis.bio-x.cn/myAnalysis.php>]{.ul}).

Results {#S0003}
=======

Participant Characteristics {#S0003-S2001}
---------------------------

The basic demographic characteristics of study population are described in [Table 1](#T0001){ref-type="table"}. A total of 432 LC patients (344 males and 88 females, age at diagnosis: 55.09 ± 11.59 years) and 430 controls (342 males and 88 females, age at diagnosis: 55.22 ± 10.73) were enrolled in our present study. There was no statistical difference in gender and age distribution between cases and control groups (*P* \> 0.05).Table 1Distributions of Age and Gender in LC Cases and Healthy ControlsVariablesCase (%)Control (%)Total*P*-valueTotal432430862Age\> 0.05^a^Mean age ± SD55.09 ± 11.5955.22 ± 10.73 \> 55209 (48%)185 (43%)394 ≤ 55223 (52%)245 (57%)468Gender\> 0.05^b^ Male344 (80%)342 (80%)686 Female88 (20%)88 (20%)176[^2]

Basic Information and Preliminary Statistics of the Selected SNPs {#S0003-S2002}
-----------------------------------------------------------------

Basic information containing SNP ID, chromosomal position, alleles, MAF distribution, *P*-HWE, call rate, ORs and 95% CIs of all the candidate SNPs were demonstrated in [Table 2](#T0002){ref-type="table"}. The call rate for all SNPs was \>99.00% among the LC cases and the controls. All candidate SNPs were in accordance with HWE (*P*-HWE \> 0.05), indicating good sample selection. From the five SNPs, the minor allele T of rs17371457 and the minor allele G of rs7554283 in the *MIR137HG* were significantly correlated with an enhanced the risk of LC (OR = 1.60, 95% CI = 1.01--1.47, *P* = 0.001; OR = 1.22, 95% CI = 1.01--1.47, *P* = 0.043, respectively).Table 2Basic Information and Allele Frequency of the Selected SNPs in *MIR137HG* GeneSNPChrPositionGene(s)RoleAllelesFrequency (MAF)*P* - HWECall Rate (%)OR (95% CI)*P* valueCasesControlsrs12138817198001230*MIR137HG*ncRNA_intronicC/T1401270.56499.20%1.12 (0.86--1.45)0.398rs9440302198027024*MIR137HG*ncRNA_intronicG/A3923601.00099.40%1.17 (0.97--1.41)0.110rs1198574198029050*MIR137HG*ncRNA_intronicA/G57470.123100.00%1.23 (0.82--1.82)0.318rs17371457198032783*MIR137HG*ncRNA_intronicT/C129850.785100.00%1.60 (1.20--2.15)0.001\*rs7554283198034489*MIR137HG*ncRNA_intronicG/C4534080.62899.80%1.22 (1.01--1.47)0.043\*[^3][^4]

Associations Between Genotype Frequencies and LC Risk {#S0003-S2003}
-----------------------------------------------------

Furthermore, the correlations between polymorphisms and LC susceptibility were analyzed based on multiple inheritance modes (codominant, dominant, recessive, and log-additive models) using logistic tests. As shown in [Table 3](#T0003){ref-type="table"}, rs17371457 was found to be correlated with an increased the risk of LC in the codominant model (C/T vs C/C: OR = 1.41, 95% CI = 1.01--1.96, *P* = 0.044; T/T vs C/C: OR = 5.14, 95% CI = 1.46--18.04, *P* = 0.011), dominant model (OR = 1.54, 95% CI = 1.12--2.13, *P* = 0.008), recessive model (OR = 4.78, 95% CI = 1.36--16.76, *P* = 0.015), and log-additive model (OR = 1.58, 95% CI = 1.18--2.11, *P* = 0.002). Rs7554283 was significantly correlated with an enhanced LC risk in the recessive model (OR = 1.39, 95% CI = 1.02--1.90, *P* = 0.038) and log-additive model (OR = 1.22, 95% CI = 1.01--1.47, *P* = 0.042). No significant correlation was observed between the remaining SNPs (rs12333983, rs3735451, rs4646437 and rs2246709) and LC risk.Table 3Significant Genetic Variants in *MIR137HG* Gene Associated with the Susceptibility of LC in Chinese Li PopulationSNPModelGenotypeControlCaseWithout AdjustmentWith AdjustmentOR (95% CI)*P*^a^-valueOR (95% CI)*P*^b^-valuers12138817CodominantT/T313 (73%)307 (71.4%)11T/C105 (24.5%)106 (24.7%)1.03 (0.75--1.41)0.8571.03 (0.75--1.41)0.851C/C11 (2.6%)17 (4.0%)1.58 (0.73--3.42)0.2501.58 (0.73--3.42)0.251DominantT/T313 (73%)307 (71.4%)10.60910.603T/C-C/C116 (27.0%)123 (28.6%)1.08 (0.80--1.46)1.08 (0.8--1.46)RecessiveT/T-T/C418 (87.4%)413 (99.6%)10.25510.256C/C11 (2.6%)17 (4.0%)1.56 (0.72--3.38)1.56 (0.72--3.38)Log-additive------1.11 (0.86--1.43)0.4131.11 (0.86--1.43)0.409rs9440302Co-dominantA/A145 (33.7%)127 (29.6%)11A/G210 (48.8%)212 (49.4%)1.15 (0.85--1.56)0.3621.15 (0.85--1.57)0.358G/G75 (17.4%)90 (21.0%)1.37 (0.93--2.02)0.1121.38 (0.93--2.04)0.107DominantA/A145 (33.7%)127 (29.6%)10.19510.191A/G-G/G285 (66.3%)302 (70.4%)1.21 (0.91--1.61)1.21 (0.91--1.62)RecessiveA/A-A/G355 (82.6%)339 (79.0%)10.18910.182G/G75 (17.4%)90 (21.0%)1.26 (0.89--1.77)1.26 (0.9--1.78)Log-additive------1.17 (0.97--1.41)0.1111.17 (0.97--1.42)0.106rs1198574Co-dominantG/G387 (89.8%)377 (87.3%)11G/A41 (9.5%)53 (12.3%)1.33 (0.86--2.04)0.1991.33 (0.86--2.04)0.202A/A3 (0.7%)2 (0.5%)0.68 (0.11--4.12)0.6790.68 (0.11--4.11)0.675DominantG/G387 (89.8%)377 (87.3%)10.24610.249G/A-A/A44 (10.2%)55 (12.7%)1.28 (0.84--1.96)1.28 (0.84--1.96)RecessiveG/G-G/T428 (99.3%)430 (99.5%)10.65410.649A/A3 (0.7%)2 (0.5%)0.66 (0.11--3.99)0.66 (0.11--3.97)Log-additive------1.22 (0.82--1.8)0.3281.21 (0.82--1.8)0.333rs17371457Co-dominantC/C349 (81%)317 (73.4%)11C/T79 (18.3%)101 (23.4%)1.41 (1.01--1.96)0.043\*1.41 (1.01--1.96)0.044\*T/T3 (0.7%)14 (3.2%)5.14 (1.46--18.04)0.011\*5.14 (1.46--18.04)0.011\*DominantC/C349 (81.0%)317 (73.4%)10.008\*10.008\*C/T-T/T82 (19.0%)115 (26.6%)1.54 (1.12--2.13)1.54 (1.12--2.13)RecessiveC/C-C/T428 (99.3%)418 (96.8%)10.015\*10.015\*T/T3 (0.7%)14 (3.2%)4.78 (1.36--16.75)4.78 (1.36--16.76)Log-additive------1.58 (1.18--2.11)0.002\*1.58 (1.18--2.11)0.002\*rs7554283Co-dominantC/C115 (26.8%)100 (23.1%)11G/C220 (51.3%)211 (48.8%)1.1 (0.79--1.53)0.5581.10 (0.79--1.53)0.556G/G94 (21.9%)121 (28%)1.48 (1.01--2.17)0.0431.48 (1.01--2.17)0.042DominantC/C115 (26.8%)100 (23.1%)10.21510.214C/G-G/G314 (73.2%)332 (76.9%)1.22 (0.89--1.66)1.22 (0.89--1.66)RecessiveC/C-G/C335 (78.1%)311 (72.0%)10.039\*10.038\*G/G94 (21.9%)121 (28.0%)1.39 (1.02--1.89)1.39 (1.02--1.90)Log-additive------1.22 (1.01--1.47)0.043\*1.22 (1.01--1.47)0.042\*[^5][^6]

Stratification Analysis by Age and Gender {#S0003-S2004}
-----------------------------------------

According to the average age, stratified analyses regarding the impact of SNPs on the risk of LC are summarized in [Table 4](#T0004){ref-type="table"}. Among those aged over 55 years, the genotype A/G-G/G of rs17371457 was associated with an increased LC risk in the codominant model (OR = 1.56, 95% CI = 1.01--2.42, *P* = 0.047). Rs17371457 significantly increased LC risk in the codominant model (CT vs CC: OR = 1.76, 95% CI = 1.05--2.93, *P* = 0.031; TT vs CC: OR = 8.32, 95% CI = 1.03--67.41, *P* = 0.047), dominant model (OR = 1.98, 95% CI = 1.20--3.25, *P* = 0.007), and log-additive model (OR = 1.97, 95% CI = 1.26--3.08, *P* = 0.003). We also found that rs7554283 was correlated with an increased risk of LC in the codominant model (G/G vs C/C: OR = 1.82, 95% CI = 1.02--3.23, *P* = 0.042) and log-additive model (OR = 1.35, 95% CI = 1.01--1.80, *P* = 0.042). No significant association was found between the five SNPs loci in *MIR137HG* and LC risk at age ≤50 years.Table 4Relationship of *MIR137HG* Polymorphisms with LC Risk Stratified by AgeSNPModelGenotypeAge (Years) ≤ 55Age (Years) \> 55ControlCaseOR (95% CI)*P* valueControlCaseOR (95% CI)*P* valuers12138817CodominantT/T182 (74.0%)158 (70.9%)1131 (71.6%)149 (72.0%)1T/C59 (24.0%)54 (24.2%)1.05 (0.68--1.61)0.83146 (25.1%)52 (25.1%)1.00 (0.63--1.59)0.990C/C5 (2.0%)11 (4.9%)2.78 (0.94--8.24)0.0656 (3.3%)6 (2.9%)0.86 (0.27--2.75)0.803DominantT/T182 (74.0%)158 (70.9%)10.429131 (71.6%)149 (72.0%)10.952T/C-C/C64 (26.0%)65 (29.1%)1.18 (0.78--1.78)52 (28.4%)58 (28.0%)0.99 (0.63--1.54)RecessiveT/T-T/C241 (98.0%)212 (95.1%)10.067177 (96.7%)201 (97.1%)10.801C/C5 (2.0%)11 (4.9%)2.75 (0.93--8.11)6 (3.3%)6 (2.9%)0.86 (0.27--2.73)Log-additive------1.26 (0.89--1.78)0.190----0.97 (0.67--1.42)0.893AlleleT423 (86.0%)370 (83.0%)10.202308 (84.2%)350 (84.5%)10.882C69 (14.0%)76 (17.0%)1.26 (0.88--1.8)58 (15.8%)64 (15.5%)0.97 (0.66--1.43)rs9440302Co-dominantA/A82 (33.3%)75 (33.8%)163 (34.2%)52 (25.1%)1A/G128 (52.0%)106 (47.7%)0.92 (0.61--1.38)0.68682 (44.6%)106 (51.2%)1.57 (0.98--2.5)0.060G/G36 (14.6%)41 (18.5%)1.28 (0.74--2.22)0.38139 (21.2%)49 (23.7%)1.55 (0.88--2.72)0.126DominantA/A82 (33.3%)75 (33.8%)10.99163 (34.2%)52 (25.1%)10.047\*A/G-G/G164 (66.7%)147 (66.2%)1 (0.68--1.47)121 (65.8%)155 (74.9%)1.56 (1.01--2.42)RecessiveA/A-A/G210 (85.4%)181 (81.5%)10.239145 (78.8%)158 (76.3%)10.509G/G36 (14.6%)41 (18.5%)1.35 (0.82--2.2)39 (21.2%)49 (23.7%)1.18 (0.73--1.9)Log-additive------1.09 (0.83--1.42)0.529----1.27 (0.96--1.67)0.099AlleleA292 (59.3%)256 (57.7%)10.600208 (56.5%)210 (50.7%)10.105G200 (40.7%)188 (42.3%)1.07 (0.83--1.39)160 (43.5%)204 (49.3%)1.26 (0.95--1.67)rs17371457Co-dominantC/C194 (78.9%)166 (74.4%)1155 (83.8%)151 (72.2%)1C/T50 (20.3%)51 (22.9%)1.17 (0.75--1.82)0.49329 (15.7%)50 (23.9%)1.76 (1.05--2.93)0.031\*T/T2 (0.8%)6 (2.7%)3.26 (0.65--16.42)0.1531 (0.5%)8 (3.8%)8.32 (1.03--67.41)0.047\*DominantC/C194 (78.9%)166 (74.4%)10.310155 (83.8%)151 (72.2%)10.007\*C/T-T/T52 (21.1%)57 (25.6%)1.25 (0.81--1.93)30 (16.2%)58 (27.8%)1.98 (1.20--3.25)RecessiveC/C-C/T244 (99.2%)217 (97.3%)10.164184 (99.5%)201 (96.2%)10.060T/T2 (0.8%)6 (2.7%)3.15 (0.63--15.81)1 (0.5%)8 (3.8%)7.46 (0.92--60.34)Log-additive------1.3 (0.88--1.92)0.190----1.97 (1.26--3.08)0.003\*AlleleC438 (89.0%)383 (85.9%)10.145339 (91.6%)352 (84.2%)10.002T54 (11.0%)63 (14.1%)1.33 (0.9--1.97)31 (8.4%)66 (15.8%)2.05 (1.31--3.22)rs7554283Co-dominantC/C65 (26.5%)59 (26.5%)150 (27.2%)41 (19.6%)1G/C127 (51.8%)103 (46.2%)0.89 (0.57--1.38)0.59593 (50.5%)108 (51.7%)1.42 (0.86--2.34)0.166G/G53 (21.6%)61 (27.4%)1.31 (0.79--2.19)0.30041 (22.3%)60 (28.7%)1.82 (1.02--3.23)0.042\*DominantC/C65 (26.5%)59 (26.5%)10.96150 (27.2%)41 (19.6%)10.072C/G-G/G180 (73.5%)164 (73.5%)1.01 (0.67--1.53)134 (72.8%)168 (80.4%)1.54 (0.96--2.48)RecessiveC/C-G/C192 (78.4%)162 (72.6%)10.109143 (77.7%)149 (71.3%)10.131G/G53 (21.6%)61 (27.4%)1.42 (0.93--2.17)41 (22.3%)60 (28.7%)1.43 (0.9--2.26)Log-additive------1.14 (0.88--1.47)0.319----1.35 (1.01--1.80)0.042\*AlleleC257 (52.4%)221 (49.6%)10.376193 (59.3%)190 (57.7%)10.050G233 (47.6%)225 (50.4%)1.12 (0.87--1.45)175 (40.7%)228 (42.3%)1.32 (1--1.75)[^7][^8]

Stratified analyses by gender were also conducted. As shown in [Table 5](#T0005){ref-type="table"}, the results revealed that rs17371457 was correlated with an enhanced risk of LC in males under the codominant model (C/T vs C/C: OR = 1.52, 95% CI = 1.01--1.80, *P* = 0.042; T/T vs C/C: OR = 14.61, 95% CI = 1.90--112.50, *P* = 0.010), dominant model (OR = 1.73, 95% CI = 1.20--2.50), *P* = 0.003), recessive model (OR = 13.41, 95% CI = 1.75--103.10, *P* = 0.013), log-additive model (OR = 1.81, 95% CI = 1.30--2.52, *P* \< 0.001) and allele model (OR = 1.85, 95% CI = 1.33--2.58, *P* \< 0.001). In the subgroup of females, we did not find a significant association between candidate SNPs in *MIR137HG* and LC risk.Table 5Relationship of *MIR137HG* Polymorphisms with LC Risk Stratified by GenderSNPModelGenotypeMaleFemaleControlCaseOR (95% CI)*P*-valueControlCaseOR (95% CI)*P*-valuers17371457Co-dominantC/C281 (82.2%)250 (72.7%)167 (76.1%)67 (76.1%)1C/T60 (17.5%)81 (23.5%)1.52 (1.04--2.21)0.030\*19 (21.6%)20 (22.7%)1.05 (0.51--2.15)0.895T/T1 (0.3%)13 (3.8%)14.61 (1.90--112.50)0.010\*2 (2.3%)1 (1.1%)0.5 (0.04--5.64)0.574DominantC/C281 (82.2%)250 (72.7%)10.003\*67 (76.1%)67 (76.1%)10.993C/T-T/T61 (17.8%)94 (27.3%)1.73 (1.20--2.50)21 (23.9%)21 (23.9%)1 (0.50--2.00)RecessiveC/C-C/T341 (99.7%)331 (96.2%)10.013\*86 (97.7%)87 (98.9%)10.567T/T1 (0.3%)13 (3.8%)13.41 (1.75--103.10)2 (2.3%)1 (1.1%)0.49 (0.04--5.54)Log-additive------1.81 (1.30--2.52)\<0.001\*----0.95 (0.51--1.77)0.867AlleleC622 (90.9%)581 (84.4%)1\<0.001\*154 (50.2%)23 (51.1%)10.873T62 (9.1%)107 (15.6%)1.85 (1.33--2.58)153 (49.8%)22 (48.9%)0.95 (23.00--0.51)rs7554283Co-dominantC/C90 (26.5%)77 (22.4%)125 (28.4%)23 (26.1%)1G/C175 (51.5%)173 (50.3%)1.16 (0.80--1.68)0.43444 (50.0%)38 (43.2%)0.94 (0.46--1.92)0.862G/G75 (22.1%)94 (27.3%)1.47 (0.96--2.27)0.07819 (21.6%)27 (30.7%)1.55 (0.68--3.49)0.297DominantC/C90 (26.5%)77 (22.4%)10.20825 (28.4%)23 (26.1%)10.735C/G-G/G250 (73.5%)2671.25 (0.88--1.78)63 (71.6%)65 (73.9%)1.12 (0.58--2.18)RecessiveC/C-G/C265 (77.9%)250 (72.7%)10.10869 (78.4%)61 (99.3%)10.173G/G75 (22.1%)94 (27.3%)1.33 (0.94--1.89)19 (21.6%)27 (30.7%)1.61 (0.81--3.18)Log-additive------1.21 (0.98--1.51)0.078----1.24 (0.82--1.86)0.305AlleleC355 (52.2%)327 (47.5%)10.08484 (47.2%)82 (47.1%)10.286G325 (47.8%)361 (52.5%)1.21 (0.98--1.49)94(52.8%)92(52.9%)1.26(82.00--0.83)[^9][^10]

Associations Between Haplotype Analyses and LC Risk {#S0003-S2005}
---------------------------------------------------

Finally, we studied the LD and haplotype analysis of candidate SNPs. As shown in [Figure 1](#F0001){ref-type="fig"}, the LD block in *MIR137HG* gene was constituted of two SNPs (rs9440302 and rs1198574). The frequency distribution of haplotypes in two groups and its association with LC risk were presented in [Table 6](#T0006){ref-type="table"}. Haplotype AG in the *MIR137HG* gene was found to prominently increase the risk of LC (OR = 1.22, 95% CI = 1.01--1.47; *P* = 0.043), other haplotypes did not display the correlativity.Table 6Haplotype Frequencies of *MIR137HG* Gene and the Association with LC RiskSNPChrPositionGene(s)RoleAllelesFrequency (MAF)*P* - HWECall Rate (%)OR (95% CI)*P* valueCasesControlsrs12138817198001230*MIR137HG*ncRNA_intronicC/T1401270.56499.20%1.12 (0.86--1.45)0.398rs9440302198027024*MIR137HG*ncRNA_intronicG/A392360199.40%1.17 (0.97--1.41)0.11rs1198574198029050*MIR137HG*ncRNA_intronicA/G57470.123100.00%1.23 (0.82--1.82)0.318rs17371457198032783*MIR137HG*ncRNA_intronicT/C129850.785100.00%1.60 (1.20--2.15)0.001\*rs7554283198034489*MIR137HG*ncRNA_intronicG/C4534080.62899.80%1.22 (1.01--1.47)0.043\*[^11][^12] Figure 1Haplotype block map for six SNPs in *MIR137HG* Gene.

SNP Functional Evaluation {#S0003-S2006}
-------------------------

In order to explore the regulatory roles of the statistically significant variants, we predicted the function of them using HaploReg v4.1 database. Six SNPs in *MIR137HG* were successfully predicted as regulatory SNPs with different biological functions ([[Supplementary Table S2](https://www.dovepress.com/get_supplementary_file.php?f=225669.docx)]{.ul}).

Discussion {#S0004}
==========

The miRNA variants have been recognized as major contributors to the pathogenesis and development of cancers. In this study, we aimed to elucidate the relationship between *MIR137HG* gene polymorphisms and LC susceptibility in Chinese Li population. The results suggested that rs17371457 and rs7554283 in the *MIR137HG* gene were correlated with an enhanced LC risk. After stratifying the sample by gender and age, correlation were found between higher risk of LC and *MIR137HG* polymorphisms (rs9440302, rs17371457 and rs7554283) at age \>55 years. Rs17371457 was related to higher LC risk in males. Similarly, the haplotype AG significantly increased LC risk in Chinese Li population. As far as we know, this is the first study to show the association of *MIR137HG* polymorphisms and LC susceptibility in Chinese Li population.

MiRNAs are involved in the major cellular processes of cancer, and *MIR137HG* belongs to the miRNA class. Previous studies showed that *MIR137HG* gene polymorphisms affect the gray matter structure in patients with schizophrenia, and it was also related to the volume of corpus callosum.[@CIT0016],[@CIT0017] At the same time, it has been reported that the methylation level of *MIR137HG* promoter was increased in a variety of cancers and was related to the expression level of MIR137. Morandi et al believed that methylation level was the key factor for early detection of oral squamous cell carcinoma (OSCC), and found that *MIR137HG* was hypermethylated in OSCC and high-grade squamous intraepithelial lesion (HGSIL).[@CIT0009] Johnson et al observed that *MIR137HG* was methylated in malignant pleural mesothelioma (MPM) cell lines. Besides, *MIR137* showed tumor inhibition function in MPM by targeting *YBX1*, which was dysregulated in MPM because of Copy number variations (CNV) and hypermethylation of the *MIR137HG* promoter.[@CIT0008] Li et al showed that *HSF1* recruited *DNMT3a* to inhibit the promoter methylation of lncRNA *MIR137HG* by targeting *GLS1* mRNA, and further reduced the expression of *MIR137HG-MIR137*, and *HSF1* stimulated *GLS1*-dependent mTOR activation to promote colorectal carcinogenesis.[@CIT0007]

Furthermore, *MIR137HG* is the host gene of *MIR137*. It is reported that *MIR137* was a tumor suppressor by inhibiting cancer proliferation, cell-cycle progression and migration,[@CIT0018],[@CIT0019] and it was lowly expressed in various cancers, such as hepatocellular carcinoma, lung cancer, colorectal cancer, gastric cancer, and cervical cancer.[@CIT0020]--[@CIT0022] Additionally, studies have shown that *MIR137* may serve as a prognostic marker in hepatocellular carcinoma (HCC) patients,[@CIT0023] and miR-137/miR-133a-TINCR pathway can be used as a promising target for tumor recurrence and prognosis in HCC patients.[@CIT0024] Researches have shown that *MIR137* inhibits tumor growth and metastasis in HCC by targeting AKT serine/threonine kinase2[@CIT0025] and the suppressive effects of *MIR137* on HCC cell proliferation and metastasis were regulated by cell division cycle.[@CIT0026] *MIR137* was down-regulated in HCC and inhibits HCC cell migration and invasion by targeting EZH2-STAT3 signaling pathway.[@CIT0027] Therefore, *MIR137HG* may also affect the expression of *MIR137* through promoter hypermethylation, thereby affecting the metastasis and growth of LC.

Significantly, the major allele of *MIR137HG* risk SNPs, including rs1625579, lead to lower levels of mature *MIR137* than those with the minor allele.[@CIT0028] A post-mortem tissue analysis also showed that the biogenesis of this miRNA may be disrupted in carriers of the rs1625579 risk genotypes.[@CIT0029] In our case--control study, we investigated the correlation between *MIR137HG* SNPs and LC risk, and the result showed that rs17371457 and rs7554283 in *MIR137HG* gene exhibited an increased risk of LC. Rs9440302, rs17371457 and rs7554283 also correlation with an increased LC risk at age \>55 years. The rs17371457 was related to higher LC risk in males. Based on these results, we hypothesized that the allele of *MIR137HG* risk SNPs (s9440302, rs17371457 and rs7554283) reduced the level of mature *MIR137*, thereby increasing the risk of LC. Additionally, the case group in our study included patients with confirmed liver cancer, excluding patients with liver cirrhosis, chronic hepatitis B and C, NAFLD, Wilson's disease and other liver diseases. Thus, the distribution of MIR137HG SNPs in other liver diseases (such as chronic B and C hepatitis, cirrhosis, NAFLD and Wilson's disease), and the relationship with liver-related diseases are also unknown. The specific mechanism of MIR137HG SNPs on LC risk and the relationship between MIR137HG SNPs and other liver diseases still need further study. Several limitations of this study should not be ignored. Firstly, current study may be limited by the source of samples, which may limit statistical capacity. Secondly, the size of sample was not large enough to rule out false negative results. So, larger sample size and more ethnic groups are needed for further verification. Despite the above limitations, the results of this study provide a scientific basis for future studies on the relationship between LC and *MIR137HG* gene SNPs.

In general, this study firstly revealed the potential role of *MIR137HG* on LC susceptibility in the Chinese Li population, which provides new insights into the pathogenesis of LC. Further studies with larger samples and well-designed methods in diverse populations are necessary to confirm our results.
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